the new standards include (i) a wound-creating pattern for therapeutic treatment versus the control; (ii) measurements of the physiological parameters of diabetes, (iii) demonstration of effectiveness for a FDA-approved wound healing agent to support the relevance of these models; and (iv) most importantly, identification of a 27-amino acid peptide, called F-8, as the core entity of Hsp90α to promote wound healing. The gene discussed is HSP90AA1; the disease is diabetes mellitus.